LVRNA009 / AIM Vaccine 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  LVRNA009 / AIM Vaccine
    Trial completion:  Clinical Trial of SARS-CoV-2 mRNA Vaccine in Chinese People (clinicaltrials.gov) -  Sep 6, 2023   
    P2,  N=420, Completed, 
    secretion, which showed good immunogenicity. Active, not recruiting --> Completed
  • ||||||||||  LVRNA009 / AIM Vaccine
    Enrollment open, Trial completion date, Trial primary completion date:  A Global Multi-center Clinical Study of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19 (clinicaltrials.gov) -  Feb 21, 2023   
    P3,  N=34000, Recruiting, 
    Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Aug 2023 --> Dec 2024
  • ||||||||||  LVRNA009 / AIM Vaccine
    Trial completion date, Trial initiation date, Trial primary completion date:  Clinical Trial of SARS-CoV-2 mRNA Vaccine(LVRNA009) as Heterologous Booster in Islamabad (clinicaltrials.gov) -  Feb 2, 2023   
    P3,  N=1100, Not yet recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Aug 2023 --> Dec 2024 Trial completion date: Jun 2024 --> Oct 2024 | Initiation date: Dec 2022 --> Apr 2023 | Trial primary completion date: Jun 2023 --> Oct 2023
  • ||||||||||  LVRNA009 / AIM Vaccine
    Journal:  Development of Bivalent mRNA Vaccines against SARS-CoV-2 Variants. (Pubmed Central) -  Nov 15, 2022   
    We previously developed an mRNA vaccine (LVRNA009) based on the S protein of the Wuhan-Hu-1 strain; the phases I and II clinical trials showed that LVRNA009 has a promising safety and immunogenicity profile...Finally, serum samples from mice immunized with Delta/BA.5 vaccine had high VNTs against all the tested pseudotyped SARS-CoV-2 strains including the Wuhan-Hu-1, Delta, and Omicron variants (p > 0.05). Therefore, a bivalent mRNA vaccine with Delta/BA.5 combination is promising to provide broad spectrum immunity against all VOCs.
  • ||||||||||  LVRNA009 / AIM Vaccine
    Trial completion date, Trial initiation date, Trial primary completion date:  Clinical Trial of SARS-CoV-2 mRNA Vaccine(LVRNA009) as Heterologous Booster in Islamabad (clinicaltrials.gov) -  Oct 27, 2022   
    P3,  N=1100, Not yet recruiting, 
    Therefore, a bivalent mRNA vaccine with Delta/BA.5 combination is promising to provide broad spectrum immunity against all VOCs. Trial completion date: Mar 2024 --> Jun 2024 | Initiation date: Sep 2022 --> Dec 2022 | Trial primary completion date: Mar 2023 --> Jun 2023
  • ||||||||||  LVRNA009 / AIM Vaccine
    Trial completion date:  Clinical Trial of SARS-CoV-2 mRNA Vaccine in Chinese People (clinicaltrials.gov) -  Oct 19, 2022   
    P2,  N=420, Active, not recruiting, 
    Trial completion date: Mar 2024 --> Jun 2024 | Initiation date: Sep 2022 --> Dec 2022 | Trial primary completion date: Mar 2023 --> Jun 2023 Trial completion date: Aug 2023 --> May 2023
  • ||||||||||  LVRNA009 / AIM Vaccine
    Enrollment closed, Trial completion date:  Clinical Trial of SARS-CoV-2 mRNA Vaccine in China (clinicaltrials.gov) -  Oct 19, 2022   
    P1,  N=144, Active, not recruiting, 
    Trial completion date: Aug 2023 --> May 2023 Recruiting --> Active, not recruiting | Trial completion date: Oct 2022 --> Oct 2023